All News

Julia Logan, BS, discusses the vital role of nutrition in cancer care, highlighting how artificial intelligence can enhance dietary recommendations for patients.

Luis Carvajal-Carmona, PhD, stresses the importance of global collaboration in cancer research to enhance understanding and treatment across diverse populations.

Ravindra Uppaluri, MD, PhD, lead investigator of the phase 3 KEYNOTE-689 trial (NCT03765918), highlights the need for a multidisciplinary approach to translate the study's findings into real-world care for patients with resectable head and neck cancer.

Ravindra Uppaluri, MD, PhD, lead investigator of the phase 3 KEYNOTE-689 trial (NCT03765918), highlights the potential of pembrolizumab (Keytruda; Merck) to improve outcomes following head and neck cancer treatment.

Andrew Kuykendall, MD, is an investigator on the phase 3 VERIFY trial (NCT05210790), findings from which demonstrate the safety, reliability, and effectiveness of rusfertide to treat polycythemia vera.

New research explores the complex relationship between female infertility and gynecological cancers, revealing minimal links and emphasizing the need for further studies.

The findings highlight important differences between therapies in managing blood glucose, blood pressure, lipids, and adverse effects in this high-risk patient population.

Adding venetoclax to decitabine-cedazuridine significantly enhanced response rates in patients with higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia.

Tocilizumab has emerged as a key treatment for rheumatoid arthritis, showing efficacy, safety, and potential cardiovascular benefits in recent studies.

As the Affordable Care Act passed its 15th anniversary this year, Supreme Court Justices continue to deliberate the fate of its preventive services mandate in Kennedy v Braidwood.

Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related health issues, but it also risks adding tens of billions in new costs, highlighting the need for smart policy strategies to ensure access, affordability, and long-term sustainability.

When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

The Trump administration is proceeding with probes into the national security implications of pharmaceutical imports.

Richard J. Nowak, MD, MS, Yale School of Medicine, explains what some early myasthenia gravis symptoms are and their impact on research efforts.

A new analysis links higher triglyceride-glucose (TyG) and TyG–body mass index (TyG-BMI) levels to increased colorectal cancer (CRC) risk, especially among women, but not mortality.

Substantial savings opportunities exist by using lower-cost biologics for patients with plaque psoriasis, according to one study.

The continued success of abelacimab throughout the AZALEA-TIMI 71 trials helps draw the drug closer to FDA approval, stated Sid Patel, MD.

The future of treating metabolic dysfunction–associated steatohepatitis (MASH) looks brighter than ever, says Naim Alkhouri, MD, as data emerges on newly developed interventions.

Asembia's AXS25 Summit will unite more than 8000 key decision-makers to explore pharmacy innovation, artificial intelligence, policy, and patient care from April 27 to May 1 at Wynn & Encore in Las Vegas, Nevada.

Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.

Even with prevention measures and timely, aggressive intervention, tumor lysis syndrome (TLS) remains life-threatening, as a case study in small cell lung cancer (SCLC) illustrates.

Following the Trump Administration’s mandate to cut $2.6 billion in NIH contracts, the Women’s Health Initiative shares HHS will close its regional centers in September.

A new study has found increased risks for liver, pancreatic, and bowel cancers following a new diagnosis of type 2 diabetes—but not all obesity-related cancers show a link.

Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.

Emerging research highlights how vitamin D boosts immunity and reduces colorectal cancer (CRC) risk by regulating inflammation and cell growth.

Emergency departments (ED) struggle to screen for social determinants of health, inhibiting quality care and impacting health disparities among vulnerable populations.

For patients with complex needs and social challenges like unstable housing, the hospital has become their de facto medical home—yet each visit is a fragmented restart, without continuity, context, or a clear path forward.

Upadacitinib showed promising results in achieving clinical and endoscopic remission in people with moderate to severe Crohn disease, including those previously treated with advanced therapies, offering a potential second-line treatment option with a manageable safety profile.